FDA
approval
· 2017-02-23
FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
Summary
FDA approved a supplemental application for Hikma Pharmaceuticals USA Inc. to market fluphenazine decanoate, a long-acting injectable antipsychotic used to trea…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for FLUPHENAZINE DECANOATE (FLUPHENAZINE DECANOATE)